|
US7666400B2
(en)
|
2005-04-06 |
2010-02-23 |
Ibc Pharmaceuticals, Inc. |
PEGylation by the dock and lock (DNL) technique
|
|
US8652484B2
(en)
|
2004-02-13 |
2014-02-18 |
Immunomedics, Inc. |
Delivery system for cytotoxic drugs by bispecific antibody pretargeting
|
|
US8491914B2
(en)
|
2004-02-13 |
2013-07-23 |
Ibc Pharmaceuticals, Inc. |
Dock-and-lock (DNL) complexes for delivery of interference RNA
|
|
US8034352B2
(en)
*
|
2005-04-06 |
2011-10-11 |
Ibc Pharmaceuticals, Inc. |
Tetrameric cytokines with improved biological activity
|
|
US7878978B2
(en)
|
2004-03-18 |
2011-02-01 |
University Of Pittsburgh- Of The Commonwealth System Of Higher Education |
Use of relaxin to increase arterial compliance
|
|
US8481041B2
(en)
|
2005-04-06 |
2013-07-09 |
Ibc Pharmaceuticals, Inc. |
Dock-and-lock (DNL) constructs for human immunodeficiency virus (HIV) therapy
|
|
US8475794B2
(en)
|
2005-04-06 |
2013-07-02 |
Ibc Pharmaceuticals, Inc. |
Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases
|
|
US20100226884A1
(en)
|
2009-01-20 |
2010-09-09 |
Immunomedics, Inc. |
Novel Class of Monospecific and Bispecific Humanized Antibodies that Target the Insulin-like Growth Factor Type I Receptor (IGF-1R)
|
|
US8883162B2
(en)
|
2005-10-19 |
2014-11-11 |
Ibc Pharmaceuticals, Inc. |
Multivalent antibody complexes targeting IGF-1R show potent toxicity against solid tumors
|
|
US9862770B2
(en)
|
2005-10-19 |
2018-01-09 |
Ibc Pharmaceuticals, Inc. |
Multivalent antibody complexes targeting IGF-1R show potent toxicity against solid tumors
|
|
WO2012024223A2
(en)
*
|
2010-08-17 |
2012-02-23 |
Immunomedics, Inc. |
Combination therapy with anti-cd74 antibodies provides enhanced toxicity to malignancies, autoimmune disease and other diseases
|
|
US9272029B2
(en)
|
2009-03-26 |
2016-03-01 |
Ibc Pharmaceuticals, Inc. |
Interferon lambada-antibody complexes
|
|
BRPI0911427A2
(pt)
*
|
2008-04-10 |
2015-11-17 |
Ibc Pharmaceuticals |
complexo por dnl (dock and lock) de anticorpo-citocina, uso de uma composição farmaceutica.
|
|
EP2305309A2
(en)
|
2008-06-13 |
2011-04-06 |
Proyecto de Biomedicina Cima, S.L. |
Conjugates for the administration of biologically active compounds
|
|
WO2010022225A1
(en)
*
|
2008-08-20 |
2010-02-25 |
Ibc Pharmaceuticals, Inc. |
Dock-and-lock (dnl) vaccines for cancer therapy
|
|
EP2346526A2
(en)
|
2008-09-22 |
2011-07-27 |
Massachusetts Institute of Technology |
Compositions of and methods of using ligand dimers
|
|
MX2011005915A
(es)
|
2008-12-03 |
2011-08-17 |
Proyecto Biomedicina Cima Sl |
Uso de modulinas solubles en fenol para el desarrollo de vacunas.
|
|
EP2393514B1
(en)
*
|
2009-02-06 |
2017-12-20 |
Sichuan Huiyu Pharmaceutical Co., Ltd. |
Dual inhibition of immunophilin/cyclophilin and emmprin immunoglobulin receptor superfamily members
|
|
US8535477B2
(en)
|
2009-02-21 |
2013-09-17 |
Sofradim Production |
Medical devices incorporating functional adhesives
|
|
EP2258398A1
(en)
|
2009-05-26 |
2010-12-08 |
Araclón Biotech, S. L. |
Albumin-amyloid peptide conjugates and uses thereof
|
|
CA2772572A1
(en)
*
|
2009-08-31 |
2011-03-03 |
Ibc Pharmaceuticals, Inc. |
Bispecific immunocytokine dock-and-lock (dnl) complexes and therapeutic use thereof
|
|
EP2473187A4
(en)
*
|
2009-08-31 |
2015-09-16 |
Immunomedics Inc |
COMPOSITIONS AND METHODS FOR USE OF IMMUNOXINS WITH RANPIRNASE (RAP) WITH HIGH CYTOTOXIC ACTIVITY
|
|
ES2655687T3
(es)
|
2009-09-11 |
2018-02-21 |
Proyecto De Biomedicina Cima, S.L. |
Composiciones terapéuticas para el tratamiento de enfermedades causadas por HPV
|
|
IN2012DN02692A
(cg-RX-API-DMAC10.html)
*
|
2009-11-05 |
2015-09-04 |
Ct Molecular Med & Immunology |
|
|
CN102665757A
(zh)
*
|
2009-12-09 |
2012-09-12 |
免疫医疗公司 |
通过双特异性抗体预靶向的用于细胞毒性药物的递送系统
|
|
EP2509629A4
(en)
*
|
2009-12-09 |
2013-06-26 |
Ibc Pharmaceuticals Inc |
DNL ("DOCK-AND-LOCK") COMPLEXES FOR INTERFERING RNA ADMINISTRATION
|
|
US10822396B2
(en)
|
2009-12-15 |
2020-11-03 |
MuHyeon CHOE |
Repeat-chain for the production of dimer, multimer, multimer complex and super-complex
|
|
US20120259099A1
(en)
*
|
2009-12-15 |
2012-10-11 |
MuHyeon CHOE |
Method for manufacturing dimers and multimers by increasing the production of bond bridges in a complex of multiple monomers and repeating chains of an adherend of a type specifically adhering to monomers
|
|
IN2012DN05101A
(cg-RX-API-DMAC10.html)
*
|
2010-01-19 |
2015-10-23 |
Immunomedics Inc |
|
|
WO2011101332A1
(en)
|
2010-02-16 |
2011-08-25 |
Proyecto De Biomedicina Cima, S.L. |
Compositions based on the fibronectin extracellular domain a for the treatment of melanoma
|
|
WO2011119836A1
(en)
|
2010-03-24 |
2011-09-29 |
Massachusetts Institute Of Technology |
Methods and compositions for cardioprotection and cardioregeneration
|
|
EP2588525A4
(en)
|
2010-06-29 |
2015-06-10 |
Covidien Lp |
MICROWAVE POWERED REACTOR AND IN SITU IMPLANT TRAINING METHOD
|
|
US8865857B2
(en)
|
2010-07-01 |
2014-10-21 |
Sofradim Production |
Medical device with predefined activated cellular integration
|
|
EP2635300A4
(en)
*
|
2010-11-03 |
2014-04-02 |
Ibc Pharmaceuticals Inc |
DOCK-AND-LOCK (DNL) CONSTRUCTS FOR THERAPY AGAINST HUMAN IMMUNE WEAKAGE VIRUS (HIV)
|
|
WO2012123269A1
(en)
|
2011-03-11 |
2012-09-20 |
Proyecto De Biomedicina Cima, S.L. |
Immunogenic compositions and methods for their use
|
|
EP2505640A1
(en)
|
2011-03-29 |
2012-10-03 |
Neo Virnatech, S.L. |
Vaccine compositions for birnavirus-borne diseases
|
|
CN103160513B
(zh)
*
|
2011-12-16 |
2015-07-01 |
中国医学科学院基础医学研究所 |
Muc1蛋白核酸适配子、复合体、组合物及其用途
|
|
EP2606897A1
(en)
|
2011-12-22 |
2013-06-26 |
Laboratorios Del. Dr. Esteve, S.A. |
Methods and compositions for the treatment of diseases caused by enveloped viruses
|
|
CN104363919A
(zh)
|
2012-06-01 |
2015-02-18 |
Ibc药品公司 |
具有改进的体内稳定性、药物代谢动力学和功效的多聚体复合物
|
|
CN102703453B
(zh)
*
|
2012-06-13 |
2013-10-30 |
江南大学 |
特异性识别链霉素的dna适配体及其应用
|
|
US20150231241A1
(en)
|
2012-08-14 |
2015-08-20 |
Ibc Pharmaceuticals, Inc. |
Combination therapy for inducing immune response to disease
|
|
US9682143B2
(en)
|
2012-08-14 |
2017-06-20 |
Ibc Pharmaceuticals, Inc. |
Combination therapy for inducing immune response to disease
|
|
AU2013302696B9
(en)
|
2012-08-14 |
2018-08-09 |
Ibc Pharmaceuticals, Inc. |
T-cell redirecting bispecific antibodies for treatment of disease
|
|
US9382329B2
(en)
|
2012-08-14 |
2016-07-05 |
Ibc Pharmaceuticals, Inc. |
Disease therapy by inducing immune response to Trop-2 expressing cells
|
|
ITRM20130138A1
(it)
|
2013-03-07 |
2014-09-08 |
Consiglio Nazionale Ricerche |
Assemblato comprendente un assorbitore della luce nel vicino infrarosso legato covalentemente ad un inibitore dell'anidrasi carbonica
|
|
US9775928B2
(en)
|
2013-06-18 |
2017-10-03 |
Covidien Lp |
Adhesive barbed filament
|
|
CA2924520C
(en)
|
2013-11-01 |
2023-09-26 |
Ibc Pharmaceuticals, Inc. |
Bispecific antibodies that neutralize both tnf-alpha and il-6: novel therapeutic agent for autoimmune disease
|
|
FR3017714A1
(fr)
*
|
2014-02-18 |
2015-08-21 |
Biomerieux Sa |
Procede et kit pour determiner la probabilite pour un patient d'evoluer vers une dengue severe
|
|
WO2015138638A1
(en)
|
2014-03-11 |
2015-09-17 |
Theraly Pharmaceuticals, Inc. |
Long acting trail receptor agonists for treatment of autoimmune diseases
|
|
US10647768B2
(en)
|
2014-05-29 |
2020-05-12 |
Macrogenics, Inc. |
Multi-chain polypeptide-containing tri-specific binding molecules
|
|
CN107250161A
(zh)
|
2015-01-26 |
2017-10-13 |
宏观基因有限公司 |
包含dr5‑结合结构域的多价分子
|
|
CN104558174A
(zh)
*
|
2015-01-29 |
2015-04-29 |
东南大学 |
一种针对睾酮的特异性纳米抗体及其应用
|
|
US11000548B2
(en)
|
2015-02-18 |
2021-05-11 |
Enlivex Therapeutics Ltd |
Combination immune therapy and cytokine control therapy for cancer treatment
|
|
US11304976B2
(en)
|
2015-02-18 |
2022-04-19 |
Enlivex Therapeutics Ltd |
Combination immune therapy and cytokine control therapy for cancer treatment
|
|
US11512289B2
(en)
|
2015-02-18 |
2022-11-29 |
Enlivex Therapeutics Rdo Ltd |
Combination immune therapy and cytokine control therapy for cancer treatment
|
|
US11318163B2
(en)
|
2015-02-18 |
2022-05-03 |
Enlivex Therapeutics Ltd |
Combination immune therapy and cytokine control therapy for cancer treatment
|
|
US11497767B2
(en)
|
2015-02-18 |
2022-11-15 |
Enlivex Therapeutics R&D Ltd |
Combination immune therapy and cytokine control therapy for cancer treatment
|
|
US11596652B2
(en)
|
2015-02-18 |
2023-03-07 |
Enlivex Therapeutics R&D Ltd |
Early apoptotic cells for use in treating sepsis
|
|
JP6803339B2
(ja)
|
2015-04-21 |
2020-12-23 |
エンリヴェックス セラピューティクス リミテッド |
治療用のプールされた血液アポトーシス細胞調製物及びそれらの使用
|
|
CN107614515B
(zh)
|
2015-05-28 |
2022-03-22 |
免疫医疗公司 |
用于抗hiv(人免疫缺陷病毒)疗法和/或疫苗的t20构建体
|
|
TWI773646B
(zh)
|
2015-06-08 |
2022-08-11 |
美商宏觀基因股份有限公司 |
結合lag-3的分子和其使用方法
|
|
PE20231958A1
(es)
|
2015-07-30 |
2023-12-06 |
Macrogenics Inc |
Moleculas de union a pd-1 y metodos de uso de las mismas
|
|
UA128469C2
(uk)
|
2015-10-08 |
2024-07-24 |
Макродженікс, Інк. |
Спосіб лікування в7-н3-експресуючого раку
|
|
EP3363447A4
(en)
*
|
2015-10-12 |
2019-07-03 |
Industry - University Cooperation Foundation Hanyang University |
ADENOVIRUS COMPLEX FOR TRANSFER AND GENE THERAPY
|
|
CN108368509B
(zh)
*
|
2015-12-04 |
2022-03-22 |
全药工业株式会社 |
改善了血中滞留性的抗il-17适体
|
|
CN108367069B
(zh)
|
2015-12-14 |
2022-08-23 |
宏观基因有限公司 |
对于pd-1和ctla-4具有免疫反应性的双特异性分子及其使用方法
|
|
US11007251B2
(en)
|
2015-12-17 |
2021-05-18 |
The Johns Hopkins University |
Ameliorating systemic sclerosis with death receptor agonists
|
|
AR108034A1
(es)
|
2016-02-17 |
2018-07-11 |
Macrogenics Inc |
Moléculas de unión a ror1, y métodos de uso de las mismas
|
|
JP6884155B2
(ja)
|
2016-02-18 |
2021-06-09 |
エンリヴェックス セラピューティクス リミテッド |
癌治療のための併用免疫療法及びサイトカイン制御療法
|
|
CN109195620B
(zh)
|
2016-04-07 |
2022-06-28 |
约翰霍普金斯大学 |
用死亡受体激动剂治疗胰腺炎和疼痛的组合物和方法
|
|
CN109069633A
(zh)
|
2016-04-15 |
2018-12-21 |
宏观基因有限公司 |
新颖的b7-h3-结合分子、其抗体药物缀合物及其使用方法
|
|
BR112019012950A2
(pt)
|
2016-12-23 |
2019-11-26 |
Macrogenics, Inc. |
molécula de ligação a adam9, composição farmacêutica, uso da molécula de ligação a adam9 e método para tratar uma doença ou condição associada ou caracterizada pela expressão de adam9 em um indivíduo
|
|
BR112019017628A2
(pt)
|
2017-02-24 |
2020-07-07 |
Macrogenics, Inc. |
molécula de ligação a cd137 x ta, composições farmacêuticas, uso da molécula de ligação a cd137 x ta, molécula de ligação a cd137, uso da molécula de ligação a cd137, molécula de ligação a her2/neu, uso da molécula de ligação a her2/neu, e uso de uma composição
|
|
WO2018162450A1
(en)
|
2017-03-06 |
2018-09-13 |
Fundación Para La Investigación Médica Aplicada |
New inmunostimulatory compositions comprising an entity of cold inducible rna-binding protein with an antigen for the activation of dendritic cells
|
|
CA3071922A1
(en)
*
|
2017-08-04 |
2019-02-07 |
The Governing Council Of The University Of Toronto |
Nanoparticle platform for antibody and vaccine delivery
|
|
CN109771658B
(zh)
*
|
2017-11-14 |
2021-12-10 |
博瑞生物医药(苏州)股份有限公司 |
靶向多臂偶联物
|
|
US11795226B2
(en)
|
2017-12-12 |
2023-10-24 |
Macrogenics, Inc. |
Bispecific CD16-binding molecules and their use in the treatment of disease
|
|
CN111787949A
(zh)
|
2018-02-15 |
2020-10-16 |
宏观基因有限公司 |
变体cd3-结合结构域及其在用于治疗疾病的组合疗法中的用途
|
|
KR102101561B1
(ko)
*
|
2018-07-25 |
2020-04-20 |
가톨릭대학교 산학협력단 |
신생혈관 표적용 조영제 조성물 및 이의 제조방법
|
|
EP3873532A1
(en)
|
2018-10-31 |
2021-09-08 |
Novartis AG |
Dc-sign antibody drug conjugates
|
|
US12252582B2
(en)
|
2019-08-29 |
2025-03-18 |
University Of Delaware |
Biofunctional thiophene monomers and polymers thereof for electronic biomedical devices
|
|
JP7745556B2
(ja)
|
2020-02-21 |
2025-09-29 |
マクロジェニクス,インコーポレーテッド |
Cd137結合分子及びその使用
|
|
US11767353B2
(en)
|
2020-06-05 |
2023-09-26 |
Theraly Fibrosis, Inc. |
Trail compositions with reduced immunogenicity
|
|
US20240279353A1
(en)
|
2020-07-06 |
2024-08-22 |
Kiromic BioPharma, Inc. |
Mesothelin isoform binding molecules and chimeric pd1 receptor molecules, cells containing the same and uses thereof
|
|
CN112156194B
(zh)
*
|
2020-09-29 |
2023-01-24 |
中国工程物理研究院核物理与化学研究所 |
一种去除177Lu溶液中内毒素的方法
|
|
CA3202233A1
(en)
|
2020-11-18 |
2022-05-27 |
Kiromic BioPharma, Inc. |
Gamma-delta t cell manufacturing processes and chimeric pd1 receptor molecules
|
|
CN115976196B
(zh)
*
|
2022-12-16 |
2024-12-06 |
深圳市人民医院 |
ErbB3作为肺动脉高压生物标志物和治疗靶点的应用
|